Share
CNBC Pro

CNBC's full interview with Biogen CEO on new Alzheimer's drug

Biogen's Alzheimer's drug Aducanumab has won FDA approval. CEO Michel Vounatsos joins CNBC's Meg Tirrell on 'Power Lunch' to discuss the approval, how the drug works and how it could change the diagnosis for Alzheimer's disease.
10:24
Mon, Jun 7 20212:56 PM EDT

watch now
VIDEO45:02
CNBC ProMad Money with Jim Cramer — June 2021
watch now
VIDEO06:57
CNBC ProCerence CEO on the future of technology in automotive space
watch now
VIDEO07:34
CNBC ProBoxed CEO on SPAC offering and expanding online wholesale retail business
watch now
VIDEO44:24
CNBC ProFast Money — June 21, 2021
watch now
VIDEO06:51
CNBC ProBlackRock's Global CIO of fixed income on inflation, housing, accelerating wages